S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The perfect AI stock under $10 (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The perfect AI stock under $10 (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The perfect AI stock under $10 (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The perfect AI stock under $10 (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:PRTG

Portage Biotech (PRTG) Stock Price, News & Analysis

$0.54
+0.13 (+31.71%)
(As of 02/22/2024 ET)
Today's Range
$0.41
$0.60
50-Day Range
$0.42
$1.89
52-Week Range
$0.34
$4.40
Volume
209,978 shs
Average Volume
54,664 shs
Market Capitalization
$9.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Portage Biotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,474.1% Upside
$8.50 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.07) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.94 out of 5 stars


PRTG stock logo

About Portage Biotech Stock (NASDAQ:PRTG)

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

PRTG Stock Price History

PRTG Stock News Headlines

H.C. Wainwright downgrades Portage Biotech on financing overhang
Portage Biotech just downgraded at H.C. Wainwright, here's why
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
PRTG: Bridging I-O: Working in Harmony with Checkpoints
Portage Biotech Reports Business and Strategic Update
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Portage Biotech GAAP EPS of -$0.29
Analyst Expectations for Portage Biotech's Future
Portage Biotech in Keytruda Collaboration With Merck
Portage Biotech Inc (PRTG) Receives a Buy from H.C. Wainwright
University Hospitals Portage Medical Center
See More Headlines
Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/29/2023
Today
2/22/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Crude petroleum & natural gas
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTG
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+1,474.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-104,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.45 per share

Miscellaneous

Free Float
10,312,000
Market Cap
$9.61 million
Optionable
Optionable
Beta
1.10
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ian B. Walters M.B.A. (Age 56)
    M.D., CEO & Chairman of Board
    Comp: $967.65k
  • Mr. Allan J. Lee Shaw CPA (Age 60)
    Chief Financial Officer
    Comp: $524.08k
  • Mr. Steven Innaimo
    Vice President of Project Management & Operations
  • Dr. Robert A. Kramer Ph.D.
    Chief Scientific Officer
  • Mr. Brian Wiley (Age 56)
    Chief Business Officer
    Comp: $220.69k
  • Mr. Justin Fairchild
    Vice President of Development
  • Mr. Joseph Ciavarella
    Chief Accounting Officer














PRTG Stock Analysis - Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRTG shares.
View PRTG analyst ratings
or view top-rated stocks.

What is Portage Biotech's stock price target for 2024?

2 Wall Street research analysts have issued 12-month target prices for Portage Biotech's stock. Their PRTG share price targets range from $6.00 to $11.00. On average, they predict the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 1,474.1% from the stock's current price.
View analysts price targets for PRTG
or view top-rated stocks among Wall Street analysts.

How have PRTG shares performed in 2024?

Portage Biotech's stock was trading at $1.82 at the beginning of the year. Since then, PRTG stock has decreased by 70.3% and is now trading at $0.54.
View the best growth stocks for 2024 here
.

Are investors shorting Portage Biotech?

Portage Biotech saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 11,000 shares, an increase of 44.7% from the January 15th total of 7,600 shares. Based on an average daily volume of 38,700 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are sold short.
View Portage Biotech's Short Interest
.

When is Portage Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our PRTG earnings forecast
.

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) announced its quarterly earnings data on Wednesday, November, 29th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.02.

Who are Portage Biotech's major shareholders?

Portage Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (10.54%), PEAK6 Investments LLC (0.29%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Portage Biotech?

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTG) was last updated on 2/23/2024 by MarketBeat.com Staff